OR WAIT null SECS
© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
July 26, 2021
Researchers from the FDA’s Center for Drug Evaluation and Research determined that the benefits of androgen receptor inhibitors outweighed the risks in men aged ≥80 years with nonmetastatic castration-resistant prostate cancer.
July 04, 2021
Ranjith Ramasamy, MD, comments on SOV2012-F1 (Kyzatrex), an oral testosterone undecanoate soft gelatin capsule.
July 02, 2021
"Early data suggest that low testosterone levels increase the risk of developing severe disease and that testosterone supplementation may provide benefit for men who are infected by the SARS-CoV-2 virus," says Mohit Khera, MD, MBA, MPH.
July 01, 2021
Researchers suggest diet may play important role in male reproductive health.
June 23, 2021
“It's quick to act and it's quick to leave the system,” says Ranjith Ramasamy, MD, of the nasal testosterone gel Natesto.
June 14, 2021
Virtual men’s health options have “improved access for patients who otherwise cannot reach doctors or who are otherwise embarrassed to go see someone in person,” says Ranjith Ramasamy, MD.
June 11, 2021
In this video, Ranjith Ramasamy, MD, explains that although testosterone therapy comes with risks, “these risks appear to be very, very small.”
June 10, 2021
Many factors play into decision-making process when weighing agents.
May 27, 2021
The new treatment is a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate.
May 26, 2021
In Urology Times’ monthly installment of Around the Practice, experts discuss adverse event management from various treatments for prostate and bladder cancer.